BACKGROUND: Medicaid covers a high-risk population typically underrepresented in clinical trial data and largely absent in observational studies of real-world cardiovascular risks associated with thiazolidinediones (TZDs), such as pioglitazone and rosiglitazone, which are used to manage type 2 diabetes. In November 2013, the FDA removed prescribing restrictions for rosiglitazone in light of new evidence that rosiglitazone did not increase the risk of heart attack compared with standard type 2 diabetes medications. Further investigation is needed to elucidate whether the risk of heart failure (HF) associated with TZDs may be exacerbated in the Medicaid population.
T hiazolidinediones (TZDs), such as pioglitazone and rosiglitazone, are widely used insulin-sensitizing agents that improve glycemic control and other surrogate outcomes in patients with type 2 diabetes. TZDs have also been shown to have potential cardiovascular benefits independent of glycemic control, 1,2 but since they cause fluid retention and peripheral edema, their use is limited due to concerns over their potential to lead to the development of heart failure (HF). Since their market release, there has been a significant body of evidence confirming the risk of developing HF with TZDs. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] While the magnitude of risk varies among the different studies, rosiglitazone has been associated with greater risk of HF compared with pioglitazone. 9, 11, 17 Rosiglitazone has also been associated in meta-analyses with increased risk for myocardial infarctions (MI) and cardiovascular mortality.
1,3-6 However, the validity of these studies has been under serious criticism. 3 In August 2007, the U.S. Food and Drug Administration (FDA) issued black box warnings about the increased HF risks for both pioglitazone and rosiglitazone. 18 Rosiglitazone's warning was subsequently amended to include increased risk of MI, 19 and under its approved Risk Evaluation and Mitigation Strategy, rosiglitazone was further restricted to be used only after patients failed to respond to other therapies and acknowledged that they understood the risks. 20 In November 2013, the FDA removed prescribing restrictions for rosiglitazone in light of new evidence that rosiglitazone did not increase the risk of heart attack compared with standard type 2 diabetes medications. 21 Following the FDA warnings, U.S. rosiglitazone use declined by more than 60%, while pioglitazone use declined only 9%. 20 Rosiglitazone and pioglitazone use stabilized and were prescribed at 1.8 million and 5.8 million treatment visits, respectively, between 2008 and 2009. 22 Between 2006 and 2009, rosiglitazone use in the Medicaid population declined from
• Both pioglitazone and rosiglitazone may increase the risk of incident heart failure.
• Metformin is the most common first-line therapy for type 2 diabetes shown to be safe and well tolerated.
What is already known about this subject
• Compared with metformin, rosiglitazone, but not pioglitazone, was associated with significant higher risk for incident heart failure when used to manage type 2 diabetes in a real-world, high-risk Medicaid population.
• This result should be considered with caution as it may not be generalizable to other risk groups. 
■■

Study Sample
The study population included beneficiaries, between the ages of 18 and 64, with at least 1 diagnosis of type 2 diabetes (ICD-9-CM codes 250.x0, 250.x2), who were started on metformin monotherapy or any drug containing pioglitazone or rosiglitazone and had no history of metformin or TZD use in the prior 6 months. For each patient, the first claim for metformin, pioglitazone, or rosiglitazone was identified and designated as the index date. Patients were excluded if they did not have complete enrollment for at least 6 months prior to the index date (pre-index period) and at least 3 months of continuous Medicaid enrollment with a prescription for any antidiabetic drug after the index date. Patients with any claims with a diagnosis of HF (ICD-9-CM codes 428, 402.11, 402.91) or pharmacy claim for digoxin during the pre-index period were excluded. The outcome of interest was the incidence of HF, defined as the first occurrence following the index date of any type of claim with any diagnosis (primary, secondary, or tertiary) of HF. The follow-up period started at the index date and ended at the incidence of HF; the date that all antidiabetic therapy was discontinued (metformin, TZDs, α-glucosidase inhibitors, amylinomimetics, gliptins, incretin memetics, insulins, meglitinides, or sulfonylureas); or disenrollment from the Medicaid program (including death), whichever occurred first. Antidiabetic treatment was considered to be discontinued if more than 60 days had passed since the end of supply of any antidiabetic drug. The date of discontinuation was taken as the dispense date plus the days supplied on the last prescription.
Information on age (18-34, 35-44, 45-54, 55-64) ; race (black, white, Hispanic, other); gender; rural (vs. urban) county residence; and MCO (vs. fee-for-service) enrollment was obtained from the index prescription claim. The Charlson Comorbidity Index (CCI) was used as a generic marker for comorbidity. 37 23 Yet, given the persistent use of pioglitazone and rosiglitazone, some physicians or patients may see a switch from rosiglitazone to pioglitazone as an appropriate response to FDA warnings, seeing that they are similar drugs and often in the same formulary tier. 17 Moreover, TZDs may be considered a better first-line therapy for some patients. Some studies have suggested TZDs have better improvement of lipid profile, lower insulin requirement, and lower hemoglobin A1c as compared with metformin. 26 TZDs are most effective in patients who do not have a long history of diabetes, since the pancreas is still producing insulin in these patients, and TZDs act by increasing tissue sensitivity to insulin. 25, 26 At issue is that nearly all of the evidence assessing the relative safety of rosiglitazone and pioglitazone has been from clinical trial data or observational studies in which special populations tend to be underrepresented. 1, 27, 28 A case in point is the Medicaid population. Socioeconomic and lifestyle factors not only lead to greater comorbidity but can also impact quality of care. [29] [30] [31] Among adults under aged 65 years, those covered by Medicaid had greater prevalence of diabetes, heart disease, and various other morbidities known to be risk factors for HF than those with private insurance or the uninsured. 32 Many patients with HF do not have symptoms or signs of HF, 33 often because of inactivity, and Medicaid patients frequently seek care in high-volume facilities where clinical focus may not include prevention of secondary complications and effective education may be limited. 29 Cultural, language, or psychosocial barriers may hinder communication between physicians and patients. 29, 31, 34 Furthermore, a variety of related factors influence patient adherence to prescribed therapies. 35, 36 The risks that have been associated with TZDs may be different in a Medicaid population given the prevalence of comorbidity and that medication management decisions can be impacted by factors that may be unique to the Medicaid population. The purpose of this study was to determine the relative risk of the development of HF in patients starting treatment with rosiglitazone or pioglitazone and metformin in real-world practice, in a high-risk group that has been largely underrepresented in clinical trials and other observational studies.
used to identify the 17 disease categories included in the CCI using ICD-9-CM diagnosis codes on medical claims in the 6-month pre-index period. The CCI was modified by excluding diabetes with and without complications. Diabetes complications (i.e., renal, ophthalmic, neurologic, and peripheral circulatory) were instead modeled explicitly using a series of indicator variables. Claims in the 6-month pre-index period were also used to construct indicators for select comorbid conditions, including coronary artery disease (ICD-9-CM codes 410, 412-414, 429.2), essential hypertension (ICD-9-CM code 401), stroke (ICD-9-CM codes 430-438), cardiac dysrhythmia (ICD-9-CM code 427), and 1 or more emergency room visit or hospitalization for hyper-or hypoglycemia. AHFS codes on pharmacy claims in the 6-month pre-index period were used to construct indicators for the use of any class of antidiabetic drugs (including insulin) and to calculate the total number (excluding insulin) used in the pre-index period. AHFS codes and information on date dispensed and days supplied on all pharmacy claims were used to ascertain the use of antidiabetic drugs and statins (= 1/0) between the index date and the end of follow-up.
Statistical Analysis
Nonparametric analyses were conducted to compare characteristics across patients who started on metformin, pioglitazone, and rosiglitazone. Stratified Kaplan-Meier analysis with logrank tests were used to compare the incidence of HF across the 3 groups.
Cox proportional hazards regression was employed to estimate hazard ratios for HF given that patients were started on pioglitazone or rosiglitazone (vs. metformin), other baseline characteristics, and the use of statins and other antidiabetic drugs during follow-up. Patients who started on a given therapy were retained in the sample even if they switched to, or added, competing therapies during the follow-up period. Variables for the use of other antidiabetic drugs (including the switch to metformin, pioglitazone, or rosiglitazone) during the follow-up period were time dependent. Thus, patients who used a given drug during follow-up did not contribute to the risk of HF associated with that drug until the date it was first dispensed. Moreover, time-dependent variables adjust for confounding due to any added risk of developing HF associated with follow-up use of metformin, pioglitazone, and rosiglitazone by patients who started on competing therapies.
Univariate Cox proportional hazards analyses were conducted to explore the impact of each variable on the overall risk of developing HF. Confounders associated with HF with P ≤ 0.200 were entered as potential covariates in the final multivariate Cox proportional hazards model. The final model was then generated using stepwise selection. Age and race were retained in the final model regardless of meeting the latter criteria, since both are known to be strongly related to heart disease.
To mitigate potential channeling bias, the risk of HF in pioglitazone patients was compared with a propensity scorematched sample of metformin patients using the same multivariate Cox proportional hazards model created in the prior step. 39 Rosiglitazone patients were compared with metformin patients using a separate propensity score-matched sample. Logistic regression was used to estimate the propensity to be initiated on pioglitazone versus metformin and rosiglitazone versus metformin, respectively. All baseline-measured covariates used in the final multivariate Cox model were included in the propensity score models, and a stepwise approach was used to select additional covariates that improved the fit of the propensity score model. Patients initiated on pioglitazone and metformin were matched 1 to 1, without replacement, using the nearest neighbor method with a caliper of 0.01. Common support was imposed by dropping pioglitazone patients whose propensity score was higher (lower) than the maximum (minimum) propensity score among the metformin patients. Using the same approach, patients initiated on rosiglitazone were matched 3 to 1 to patients initiated on metformin. Covariates were considered balanced between treatment groups if a twosided t-test of the difference in means indicated P < 0.050.
In a secondary analysis, we extended all of the previously described methods to compare the risk of developing HF associated with rosiglitazone versus pioglitazone in the subsample of patients who started on TZDs. Patients initiated on rosiglitazone were matched 1 to 1 to patients initiated on pioglitazone using the same approach.
■■ Results
A total of 6,271 type 2 diabetic patients met the inclusion criteria: 5,548 (88%) started on metformin; 413 (7%) started on pioglitazone; and 310 (5%) started on rosiglitazone (Figure 1 ). The annual proportion of patients in the sample started on metformin grew from 87% in 2006 to 93% in 2010. The proportion started on pioglitazone stayed at 5%-6% over this period, while the proportion started on rosiglitazone dropped from 6.5% to 1.6% after 2006.
The length of follow-up ranged from 1 to 1,643 days (4.5 years). Mean follow-up was 582 days (1.6 years). HF incidence was 7.7% for the sample: 7.0% (n = 389) among patients started on metformin; 8.0% (n = 33) for pioglitazone; and 19% (n = 59) for rosiglitazone (Table 1) . Unadjusted Kaplan-Meier survival curves for the 3 patient groups are presented in Figure 2 . The plot shows little difference in the incidence of HF between patients started on metformin and pioglitazone at any length of follow-up. However, patients started on rosiglitazone had greater incidence compared with patients started on either metformin (P <0.001) or pioglitazone (P = 0.005). These differences remained relatively constant across most of the follow-up period.
Univariate analyses (Appendix A, available in online article) showed greater overall risk of HF in patients with comorbidities, renal or neurologic diabetes complications, and at older ages. The risk of HF was higher in patients who used insulin in the pre-index or follow-up periods. Compared with other coverage groups, HF risk was nearly 2.2 (P < 0.001) and 4.8 (P < 0.001) times higher for patients with Age, Blind, or Disabled or Age, Blind, or Disabled/Long-Term Care coverage. Patients enrolled in an MCO at the index date had lower incidence of HF than fee-for-service patients. White patients had lower overall risk of developing HF (hazard ratio [HR] = 0.59, P = 0.041) than black patients only within patients started on TZDs. While there appeared to be a downward trend in the annual risk of developing HF in the univariate analysis, no trend was evident among patients started on TZDs nor after controlling for other factors.
Pioglitazone or Rosiglitazone Compared with Metformin
Significant differences between patients who started on metformin and TZDs were found for several baseline comorbidity, antidiabetic drug, and coverage variables as well as for age and race (Tables 1 and 2) . Compared with metformin patients, proportionately more patients who started on TZDs had a CCI greater than 1 and diabetes-related complications. TZD patients were more likely to have used insulins and sulfonylureas in the pre-index and follow-up periods and were more likely to have used gliptins, incretin memetics, and meglitinides, as well as statins during follow-up. TZD patients tended to be younger than metformin patients and more likely to be enrolled in an MCO at the index date. TZD patients were more likely than metformin patients to be enrolled in Medicaid under Age, Blind, or Disabled or Age, Blind or Disabled/LongTerm Care coverage. Table 3 reports estimated HRs and 95% confidence intervals (CI) from the multivariate Cox proportional hazards model on the full sample. There was no difference between pioglitazone and metformin patients after controlling for other factors, but rosiglitazone patients were at 57% (HR = 1.57, 95% CI = 1.15-2.15, P = 0.005) greater risk of being diagnosed with HF compared with metformin patients. A chi-squared test indicated a significant difference in risk (P = 0.049) between pioglitazone and rosiglitazone patients. Similar results were found using samples that propensity-score matched pioglitazone and rosiglitazone patients with metformin patients. There was no difference in the risk of developing HF between patients started on pioglitazone and metformin, but a significantly higher risk was present among patients started on rosiglitazone over metformin (HR = 1.79, 95% CI = 1.16-2.76, P = 0.009).
In the sample of pioglitazone and matched metformin patients, patients who switched to rosiglitazone during followup had higher risk (HR = 2.40, 95% CI = 0.99-5.83, P = 0.052) of developing HF after the change in therapy. On the other hand, patients who started on pioglitazone had lower risk (HR = 0.19, 95% CI = 0.04-0.86, P = 0.030) after switching to metformin. Higher CCI, coronary artery disease, cardiac dysrhythmia, follow-up insulin use, older age, and Age, Blind, or Disabled coverage status were all factors that significantly increased the risk of HF in the final multivariate model (Appendix B, available in online article). Statin use during follow-up was protective against the development of HF.
There was no evidence of nonproportional hazards for patients who started on pioglitazone or rosiglitazone over metformin. There was little concern for multicollinearity, since the variance inflation factors for all potential covariates in the models were < 3.0. All baseline covariates in the final Cox model were significant predictors in the logistic regression models used to propensity score-matched pioglitazone and rosiglitazone patients with metformin patients, as were index year, MCO enrollment, rural residence, pre-index use of gliptins and insulin, and the total number of other antidiabetic drugs taken in the pre-index period. All covariates were balanced across the matched groups. The minimal detectable effect size was determined using the stpower cox command available in the STATA 13.0 statistical software package (StataCorp, College Station, TX). Assuming 80% statistical power with 6,271 After exclusion of 613 patients aged < 17 years, 2,757 patients aged > 64 years, and 183 patients with age undetermined n = 24,456
After exclusion of 16,180 patients with < 6 months of continuous enrollment prior to index date, 1,565 patients with < 3 months follow-up, and 11 patients missing enrollment information n = 6,700
After exclusion of 390 patients with heart failure diagnosis and 39 patients prescribed digoxin within 6 months prior to index date n = 6,271
Patients started on metformin n = 24,456
Patients started on pioglitazone n = 413
FIGURE 1
Flowchart of Patient Sample Selection observations (92.3% censored), the minimal detectable HRs corresponding to pioglitazone (SD = 0.248, R 2 = 0.013) and rosiglitazone (SD = 0.217, R 2 = 0.123) were equal to 1.40 and 1.45 in the nonmatched sample, respectively. For the propensity score-matched analyses, the minimal detectable HRs were 1.48 for pioglitazone (91.5% censored, SD = 0.500, R 2 = 0.005) and 1.41 for rosiglitazone (86.1% censored, SD = 0.478, R 2 = 0.018).
Rosiglitazone Compared with Pioglitazone
There were few differences between patients started on pioglitazone and rosiglitazone. More rosiglitazone patients had Age, Blind, or Disabled coverage than pioglitazone patients, but both groups were equally likely to have Age, Blind, or Disabled/Long-Term Care coverage. Rosiglitazone patients were more likely than pioglitazone patients to be black and less likely to be white or other race. They were also more likely to have experienced cardiac dysrhythmia in the pre-index period and to have used incretin memetics during follow-up. Patients started on rosiglitazone were at 53% (HR = 1.53, 95% CI = 0.99-2.48, P = 0.056) higher risk of HF compared with patients started on pioglitazone (Table 3) . Using a sample of rosiglitazone patients matched to pioglitazone patients, patients started on rosiglitazone were at 72% (HR = 1.72, 95% CI = 1.08-2.74, P = 0.023) higher risk. Higher CCI and follow-up insulin use were still associated with increased risk, and statin use during follow-up was still protective (Appendix C, available in online article). The final model did not include time-dependent indicators for switching/adding rosiglitazone, pioglitazone, or metformin, since these variables were uninformative.
The baseline covariates included in the final model used with the subsample of TZD patients were not significant predictors for starting rosiglitazone over pioglitazone but were balanced nonetheless in the propensity matched sample. Significant predictors did include the index year; cardiac dysrhythmia; total number of other antidiabetic drugs in the pre-index period; MCO enrollment; and the pre-index use of incretin memetics, meglitinides, and sulfonylureas. Assuming 80% statistical power with 723 observations (82.3% censored), the minimal detectable HR corresponding to rosiglitazone (SD = 0.500, R 2 = 0.007) was equal to 1.44. Given 600 observations (85.8% censored) in the propensity score-matched sample, the minimal detectable HR on rosiglitazone (SD = 0.500, R 2 = 0.012) was 1.46.
■■ Discussion
The results show that, compared with Medicaid patients started on metformin, there was a significant higher risk of developing HF if patients started rosiglitazone but not pioglitazone. This relationship was evident with and without controlling for possible confounders. Controlling for other factors, the risk of developing HF was at least 57% (P = 0.005) greater for patients started on rosiglitazone compared with metformin. While each drug has grounds for which it could be considered first-or second-line therapy for diabetic patients, 26 we cannot observe lab values that may have informed physician decisions using claims-based data. Yet, even after matching rosiglitazone and pioglitazone patients with similar metformin patients, 
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however, there were few observations with which to precisely estimate the risk of the combination therapies relative to TZD monotherapies. We did include sulfonylurea monotherapy as a potential covariate in our analysis but found no significant impact on the risk of developing HF in our sample of patients started on metformin or TZDs. Patients who used insulin during the follow-up period were at greater risk of developing HF. Despite FDA warnings of increased risk of HF with concurrent insulin and TZD use, the interaction of TZD treatment with the time-dependent insulin variable was not a significant factor in the model.
Limitations
Some retrospective studies investigating the risk of HF with non-TZD therapies suggested that the severity and duration of diabetes was responsible for HF risk and not the drugs themselves. 41 With censored claims data, we could not directly assess the severity or duration of the disease. However, assuming this lack of information affects all comparison groups, it should not affect the relative risk comparisons. The risk of HF associated with TZDs may also increase with longer exposure. 11 Yet, the survival analysis used in this study was not amenable to control for the duration of therapy within the follow-up period. Over 50% of patients who started metformin remained using metformin through their entire followup ( Table 2 ). The median time between discontinuing initial treatment with pioglitazone and rosiglitazone and the end of the patients' follow-up was 8 days and 469 days, respectively. Thus, the relative risk of HF associated with rosiglitazone may be underestimated given that we did not directly control for the shorter duration of rosiglitazone use compared with pioglitazone or metformin use.
The observation period spans the period before and after the black box warnings for HF were placed on both TZDs and prescribing restrictions were placed on rosiglitazone. To the extent that patients determined to be at higher risk for HF were channeled by physicians away from rosiglitazone or pioglitazone in the postwarning period, we might expect the relative risk of HF associated with rosiglitazone or pioglitazone to be underestimated. To mitigate potential channeling bias, multivariate and propensity score matching approaches using the index year and other risk factors were employed. However, given the lack of clinical data provided in administrative claims, the effectiveness of either approach is uncertain.
It also remains that perhaps the practice styles, level of expertise, or cultural competency of health care professionals may be a concern for bias. By design, though, Medicaid reimbursement and incentives structures somewhat limit variations in practice style. Therefore, despite the possibility that patients may see various health care professionals during their course of care, the lack of information on providers in our study should not pose any serious validity threat. rosiglitazone patients exhibited 79% (P = 0.009) higher risk of developing HF compared with metformin patients, and pioglitazone patients were still not at significant greater risk.
Our results depart from the findings of ADOPT (A Diabetes Outcomes Progression Trial), which found that the risk of developing HF was similar in patients treated with rosiglitazone and metformin. 15 However, this is the first study to compare the risk of HF between metformin and both pioglitazone and rosiglitazone as they are used in real-world practice in a highrisk Medicaid population. In accordance with most (but not all) prior studies, 4, 8, 9, 10, 12, 15, 40 the results show that the risk of HF was higher in rosiglitazone patients compared with pioglitazone patients: 53% (P = 0.056) higher in the multivariate model and 78% (P = 0.023) higher in the propensity-matched sample.
Metformin therapy was used as the comparator. Since metformin is the guideline recommended first-line therapy for treating diabetes, 24 it is the most common antidiabetic drug prescribed in the Medicaid population. 23 Like TZDs, metformin serves as an insulin sensitizer, and since it has been used in clinical therapy for many years, there is clear evidence of its effectiveness and safety. Sulfonylureas are also a commonly used therapy in the Medicaid population. 23 One large retrospective study found that metformin was associated with reduced risk of HF compared with sulfonylureas but found no other differences between metformin, sulfonylureas, pioglitazone, and rosiglitazone. 41 Our definition of TZDs included TZD and sulfonylurea (glimepiride) combinations; 29 especially given expanding Medicaid enrollment and high prevalence of such high-cost diseases such as diabetes and HF. 42, 43 After the FDA warnings and of the risks associated with TZDs, all but 2 states' Medicaid programs still provided coverage for rosiglitazone, and all states provided coverage for pioglitazone. 23 With the most recent FDA action, treatment decisions are still mostly in the hands of prescribers and their patients. This study contributes to the literature by showing the difference in the risks of developing HF associated with metformin, pioglitazone, and rosiglitazone in a high-risk, largely African-American and underrepresented Medicaid population. The findings suggest that health care professionals should continue to use caution when choosing to prescribe TZDs over metformin. For patients who may particularly benefit from TZD therapy, pioglitazone showed no difference in the risk of HF, and clinicians should carefully weigh benefits against risk before prescribing a therapy. 
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